Gilead Sciences Inc.’s stock rose Thursday morning after the biotech company’s Kite Pharma unit gained federal approval for its flagship cell-treatment therapy for adults with advanced lymphoma. The Food and Drug Administration’s approval Wednesday of Kite’s treatment represented a rapid payoff...